Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors

Inclusion Criteria: * Subject must have a histologically or cytologically confirmed non-hematologic malignancy. * Subject must have an ECOG Score of 0-2. * Adequate organ function. Exclusion Criteria: * Subject has received targeted VEGF/PDGF therapy (tyrosine kinase inhibitor) therapy. Prior Avastin allowed. * Subject has untreated brain or meningeal metastases. * History of greater than 10% weight loss. * Has clinically relevant hemoptysis. * Subject has proteinuria CTC grade \> 1. * Must not have had radiation therapy or major surgery within 21 days of study day 1. * The subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure (DBP) \> 100 mmHg or systolic blood pressure (SBP) \> 150 mmHg. Subjects may be re-screened if blood pressure is shown to be controlled with or without intervention. * The subject has a documented left ventricular ejection fraction (LVEF) \< 50%.